The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Cross-talk between LOX-1 and PCSK9 in vascular tissues
Abstract
AIMS: Lectin-like ox-LDL receptor-1 (LOX-1) plays an important role in inflammatory diseases, such as atherosclerosis. Proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates LDL receptor degradation and influences serum LDL levels. The present study was designed to investigate the possible interaction between PCSK9 and LOX-1. METHODS AND RESULTS: In the first set of experiments, human vascular endothelial cells and smooth muscle cells were studied at baseline and after lipopolysaccharide (LPS) treatment (to create an inflammatory state). Both PCSK9 and LOX-1 were strongly induced by LPS treatment. To define the role of PCSK9 in LOX-1 expression, cells were transfected with siRNA against PCSK9, which resulted in reduced LOX-1 expression and function. On the other hand, cells exposed to recombinant hPCSK9 revealed enhanced LOX-1 expression (P < 0.05). To determine whether LOX-1 also regulates PCSK9, cultured cells in which LOX-1 was knocked down by siRNA expressed less PCSK9, whereas those transfected with hLOX-1 cDNA showed increased PCSK9 expression. The second set of experiments was carried out in wild-type (WT) and gene knockout (KO; LOX-1 and PCSK9) mice; LOX-1 KO mice showed much less PCSK9 (P < 0.05 vs. WT mice). PCSK9-KO mice showed much less LOX-1 (P < 0.05 vs. WT mice). Furthermore, we observed that mitochondrial reactive oxygen species (mtROS) plays an initiating role in the LOX-1/PCSK9 interaction, since mtROS induction enhanced and its inhibition reduced the expression of both PCSK9 and LOX-1. We also found that both LOX-1 and PCSK9 regulate adhesion molecules vascular cell adhesion molecule-1 expression. Finally, oxidized low-density lipoprotein and tumour necrosis factor-α, pro-inflammatory stimuli besides LPS, regulated PCSK9 expression that is mediated by the NF-κB signalling pathway. CONCLUSIONS: These observations suggest that LOX-1 and PCSK9 positively influence each other's expression, especially during an inflammatory reaction. mtROS appear to be important initiators of PCSK9/LOX-1 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Zhang, D.-W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702027200 · Cited by 788
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681
PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway
Wu, C.-Y., Tang, Z.-H., Jiang, L., Li, X.-F., Jiang, Z.-S., & Liu, L.-S. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1028-6 · Cited by 190
Kosenko, T., Golder, M., Leblond, G., Weng, W., & Lagace, T. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421370 · Cited by 181
Cited by
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
“PCSK9 induces LOX-1 expression and in turn, LOX-1 activation upregulates PCSK9 expression in VSMCs, which is a positive feedback regulation between the two.(210) PCSK9 and LOX-1 share many cellular signaling pathways activating vascular inflammation and cellular apoptosis (Fig.”
BackgroundMechanisms of foam cell formation in atherosclerosis
Chistiakov, D. A., Melnichenko, A. A., Myasoedova, V. A., Grechko, A. V., & Orekhov, A. N. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1575-8 · Cited by 742
Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation
Marchio, P., Guerra-Ojeda, S., Vila, J. M., Aldasoro, M., Victor, V. M., & Mauricio, M. D. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8563845 · Cited by 621
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
Severino, P., D'Amato, A., Pucci, M., Infusino, F., Adamo, F., Birtolo, L. I., Netti, L., Montefusco, G., Chimenti, C., Lavalle, C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218118 · Cited by 349
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
Tang, Z.-H., Peng, J., Ren, Z., Yang, J., Li, T.-T., Li, T.-H., Wang, Z., Wei, D.-H., Liu, L.-S., Zheng, X.-L., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.023 · Cited by 291
LOX-1: Regulation, Signaling and Its Role in Atherosclerosis
Kattoor, A. J., Goel, A., & Mehta, J. L. (2019) · Antioxidants · doi:10.3390/antiox8070218 · Cited by 253
Self-citationPCSK9 and inflammation: a review of experimental and clinical evidence
Momtazi-Borojeni, A. A., Sabouri-Rad, S., Gotto, A. M., Pirro, M., Banach, M., Awan, Z., Barreto, G. E., & Sahebkar, A. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz022 · Cited by 188
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
Ding, Z., Liu, S., Wang, X., Theus, S., Deng, X., Fan, Y., Zhou, S., & Mehta, J. L. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy079 · Cited by 147
“Previously we showed that LPS induces PCSK9 expression in vascular smooth muscle cells.(12) In this study, we observed that TNF-a increased the expression of PCSK9 and all SRs (Figure 1A) in a dose-dependent manner.”
InfluentialSelf-citationInhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Navarese, E. P., Kołodziejczak, M., Kereiakes, D. J., Tantry, U. S., O'Connor, C., & Gurbel, P. A. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2994 · Cited by 77
“Recent studies indicate a cross-reaction between PCSK9 and lectin-like oxLDL receptor-1 that leads to a mutually amplified proinflammatory response (14).”
BackgroundExpanding biology of PCSK9: roles in atherosclerosis and beyond
Seidah, N. G., & Garçon, D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01057-z · Cited by 76
Hofmann, A., Brunssen, C., & Morawietz, H. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2017.10.002 · Cited by 68
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sundararaman, S. S., Döring, Y., & van der Vorst, E. P. C. (2021) · Biomedicines · doi:10.3390/biomedicines9070793 · Cited by 67
Insight into the Evolving Role of PCSK9
Maligłówka, M., Kosowski, M., Hachuła, M., Cyrnek, M., Bułdak, Ł., Basiak, M., Bołdys, A., Machnik, G., Bułdak, R. J., & Okopień, B. (2022) · Metabolites · doi:10.3390/metabo12030256 · Cited by 41
Safaeian, L., Mirian, M., & Bahrizadeh, S. (2022) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1788605 · Cited by 32
Zulkapli, R., Muid, S. A., Wang, S. M., & Nawawi, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065098 · Cited by 27
“PCSK9 expression was more significant in smooth muscle cells (SMC) than in endothelial cells (EC) upon LPS stimulation [34,48].”
BackgroundKoskinas, K. C., Windecker, S., Buhayer, A., Gencer, B., Pedrazzini, G., Mueller, C., Cook, S., Muller, O., Matter, C. M., Räber, L., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23112 · Cited by 26
(2023) · PubMed Central · Cited by 16
Lupo, M. G., Marchianò, S., Adorni, M. P., Zimetti, F., Ruscica, M., Greco, M. F., Corsini, A., & Ferri, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084114 · Cited by 15
Metadata
- Authors
- Ding, Z., Liu, S., Wang, X., Deng, X., Fan, Y., Shahanawaz, J., Shmookler Reis, R. J., Varughese, K. I., Sawamura, T., & Mehta, J. L.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-06-19
- Volume
- 107
- Issue
- 4
- Pages
- 556-567
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W2194274372
- Cited by
- 233
- References
- 6
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.